Si-Ning Liu (Sining Liu)

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Blood cancer journal

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Wei Cui, Xin-Yue Zhang, Zheng Li, Hai-Ping Dai, Jia Yin, Qing-Ya Cui, Si-Ning Liu, Li-Qing Kang, Lei Yu, De-Pei Wu, Xiao-Wen Tang
Long-term follow-up of tandem CD19/CD22 CAR T-Cells in r/r B-ALL patients with high-risk features. American journal of hematology (2023)